1. Home
  2. PRAX vs FLR Comparison

PRAX vs FLR Comparison

Compare PRAX & FLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$295.08

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Fluor Corporation

FLR

Fluor Corporation

HOLD

Current Price

$46.62

Market Cap

6.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
FLR
Founded
2015
1912
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
6.7B
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
PRAX
FLR
Price
$295.08
$46.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
6
Target Price
$572.13
$53.50
AVG Volume (30 Days)
309.6K
2.5M
Earning Date
05-01-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,503,000,000.00
Revenue This Year
N/A
$6.15
Revenue Next Year
$6,395.88
$7.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.70
$29.20
52 Week High
$354.87
$57.50

Technical Indicators

Market Signals
Indicator
PRAX
FLR
Relative Strength Index (RSI) 41.40 52.13
Support Level $290.36 $39.37
Resistance Level $322.32 $52.05
Average True Range (ATR) 16.52 1.60
MACD -3.70 -0.26
Stochastic Oscillator 17.39 50.74

Price Performance

Historical Comparison
PRAX
FLR

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About FLR Fluor Corporation

Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.

Share on Social Networks: